

DRUG PRIOR AUTHORIZATION COMMITTEE

June 18, 2015

TENTATIVE AGENDA

Department of Natural Resources
1101 Riverside Dr.
Lacharette/Nightengale Rooms
Jefferson City, MO

10:00 - 10:05	Welcome, Announcements and Introductions	Chairman
10:05 - 10:15	Minutes Review	Discussion/Approval
10:15 - 10:25	Pharmacy Program/ Budget Update	Steve Calloway/Andrew Haslag
10:25 - 10:35	DUR Update	Steve Calloway

Old Business

10:35 – 10:45	A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Steve Calloway
---------------	--------------------------------------------------------------------------------------------------------------	----------------

New Business

10:45 – 11:30	B. Proposed Actions - New Drug/Product Review (See website and Attached Summary) <ul style="list-style-type: none">i. Open Accessii. Clinical Edit/Step Therapyiii. PDL Productsiv. Prior Authorization<ul style="list-style-type: none">• Discussion• Public Hearing• Decision	Steve Calloway
---------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------

11:30 – 11:45	C. <u>Clinical Edits</u> <ul style="list-style-type: none">I. Atypical Antipsychotics Clinical Edit<ul style="list-style-type: none">• Discussion• Public Hearing• Decision	
---------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

11:45 – 1:00	D. <u>Preferred Drug List (PDL)</u> <ul style="list-style-type: none">I. Amylin Analogs<ul style="list-style-type: none">• Discussion• Public Hearing• Decision	
--------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

- II. **Antihyperuricemic Agents**
 - Discussion
 - Public Hearing
 - Decision
- III. **Bile Salts Agents**
 - Discussion
 - Public Hearing
 - Decision
- IV. **Biologics – Disease Modifying Anti-Rheumatic Drugs (DMARDs/Immunomodulators)**
 - Discussion
 - Public Hearing
 - Decision
- V. **Bone Deossification Suppression Agents (including Calcitonin)**
 - Discussion
 - Public Hearing
 - Decision
- VI. **BPH Agents (formerly Androgen Hormone Inhibitors)**
 - Discussion
 - Public Hearing
 - Decision
- VII. **Cryopyrin-Associated Periodic Syndrome (CAPS) Agents**
 - Discussion
 - Public Hearing
 - Decision
- VIII. **DPP-IV (Dipeptidyl Peptidase-4) Inhibitors**
 - Discussion
 - Public Hearing
 - Decision
- IX. **Electrolyte Depleters (Phosphate Binders)**
 - Discussion
 - Public Hearing
 - Decision
- X. **Fluoroquinolones – Oral**
 - Discussion
 - Public Hearing
 - Decision
- XI. **GLP-1 Receptor Agonists (Anti-Diabetic Mimetics)**
 - Discussion
 - Public Hearing
 - Decision

- XII. Growth Hormones**
 - Discussion
 - Public Hearing
 - Decision
- XIII. Hematopoietic Agents**
 - Discussion
 - Public Hearing
 - Decision
- XIV. Hepatitis C Therapy**
 - Discussion
 - Public Hearing
 - Decision
- XV. Ribavirins**
 - Discussion
 - Public Hearing
 - Decision
- XVI. Insulins**
 - Discussion
 - Public Hearing
 - Decision
- XVII. Insulins – Long Acting**
 - Discussion
 - Public Hearing
 - Decision
- XVIII. Insulins – Mix**
 - Discussion
 - Public Hearing
 - Decision
- XIX. Insulins – Rapid Acting**
 - Discussion
 - Public Hearing
 - Decision
- XX. Intravaginal Antibiotics**
 - Discussion
 - Public Hearing
 - Decision
- XXI. Macrolides – Adult**
 - Discussion
 - Public Hearing
 - Decision
- XXII. Macrolides – Pediatric**
 - Discussion
 - Public Hearing
 - Decision

- XXIII. Multiple Sclerosis (MS) Agents**
 - Discussion
 - Public Hearing
 - Decision
- XXIV. Oral Anti-Diabetics: Alpha-Glucosidase Inhibitors**
 - Discussion
 - Public Hearing
 - Decision
- XXV. Oral Anti-Diabetics: Biguanides**
 - Discussion
 - Public Hearing
 - Decision
- XXVI. Oral Anti-Diabetics: Combinations**
 - Discussion
 - Public Hearing
 - Decision
- XXVII. Oral Anti-Diabetics: Meglitinides**
 - Discussion
 - Public Hearing
 - Decision
- XXVIII. Oral Anti-Diabetics: Sulfonylureas 2nd Generation**
 - Discussion
 - Public Hearing
 - Decision
- XXIX. Oral Anti-Diabetics: Thiazolidinediones**
 - Discussion
 - Public Hearing
 - Decision
- XXX. Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors**
 - Discussion
 - Public Hearing
 - Decision
- XXXI. Tetracyclines**
 - Discussion
 - Public Hearing
 - Decision
- XXXII. Urinary Tract Antispasmodics**
 - Discussion
 - Public Hearing
 - Decision

E. Preferred Drug List Classes for Sept/Oct

- i. Process Discussion
- ii. Therapeutic classes/to be announced at meeting

1:00

LUNCH

1:15-1:30

Program Utilization Information-Xerox Update

Steve Calloway/
Josh Moore

1:30-1:50

Other Business

- *“Top 25” Drugs by Cost/Claims*
- *Clinical Edit Summary Report*
- *Call Center Statistics*

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly

NEXT MEETING: September 17, 2015

Department of Natural Resources

Lacharrette/Nightengale Rooms

1101 Riverside Dr.